Leaders of Holden Comprehensive Cancer Center at the University of Iowa announced today that they appointed Michael Henry, PhD, the Center's new deputy director for research, effective July 1.
Henry joined Holden Comprehensive Cancer Center in 2004 after being recruited from Millennium Pharmaceuticals. He has served as program leader for the Cancer Signaling and Experimental Therapeutics program since 2009.
Henry is an associate professor in the Department of Molecular Physiology and Biophysics with a secondary appointment in pathology. His National Cancer Institute (NCI)-funded research program explores the biology of prostate cancer progression and metastasis with efforts in therapeutic and prognostic biomarker discovery.
George Weiner, MD, director of Holden Comprehensive Cancer Center, said Henry brings a broad base of experience in both academia and industry, and that he looks forward to working with him in his new leadership role.